Our Strategy & Vision

Our Strategy & Vision

ValiRx is a biotechnology oncology focused company specialising in developing novel therapeutics for cancer and associated biomarkers. It aims to make a significant contribution in “precision” medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company’s business model focuses on out-licensing therapeutic candidates during the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is constantly in licensing discussions and actively explore collaborative opportunities with major players in the oncology field.

ValiRx’s four therapeutics drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and grants together with commercial rights and agreements. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments have often relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack specific cancer cells only, these can less toxic and more effective treatments are now possible. New drugs in this group—such as those in ValiRx’s pipeline development plans to greatly improve outcomes for cancer patients.

The Company listed on the Alternative Investment Market (“AIM”) of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL:LON.


ValiRx operates through the following divisional companies:



ValiPharma is a biopharmaceutical division of ValiRx focused on developing personalised medicines to bring more advanced therapeutic options for the treatment of cancer.

Currently, ValiPharma is primarily focused on two drug candidates in both clinical and/or in late stage pre-clinical development. -androgen independent prostate cancer (VAL201), hormone refractory prostate cancer (VAL201), endometriosis (VAL301) and gene activity regulation (VAL101).

VAL201 – VAL201 is a peptide with a unique mechanism of action, which was first developed by academics partly with support from Cancer Research UK. It has performed well in its Phase l/ll Clinical Trial in patients with advanced prostate cancer (APC) and as confirmed to date in the fifth cohort of the trial that VAL201 is well tolerated and safe. The trial continues to show further evidence of a reduction in PSA levels and stabilisation of the disease.

VAL301 The Company continues with the pre-clinical development of VAL301, which is the proposed reformulation of VAL201 for a new indication, endometriosis. This is a gynaecological condition, characterised by endometrial-like tissue found outside of the uterine cavity. Endometriosis is a chronic and debilitating condition and it represents one of the major causes of female infertility. Pre-clinical data suggests that VAL301 will provide protection from the oestrogenic effects on uterine tissue, whilst maintaining bone density and fertility – a potentially significant development in the medical treatment of endometriosis and other gynaecological conditions.

VAL101 – VAL101 is currently in the target selection and drug optimisation phase to block/silence the expression of Bcl-2, which has been identified inter alia in Pancreatic Cancer.



ValiSeek is ValiRx’s joint venture company with Tangent Reprofiling Limited (a SEEK group company), which was formed in 2014 and has progressed product VAL401 through pre-clinical development and through a pilot Phase II clinical trial for the treatment of non small cell lung cancer. VAL401 is a reformulation of risperodone which has a well-established safety record derived from decades of clinical use in the treatment of psychosis. The reformulation enables anti-cancer activity, and this is the subject of multiple granted patents in US and other world territories.

VAL401 completed its first clinical trial in Q3 2017 an oral treatment of late stage non-small cell lung cancer, adenocarcinoma in a pilot Phase II Clinical Study in Tbilisi, Georgia. The study measured the impact of VAL401 treatment on measures of progression-free survival, quality of life and overall survival of the patients. Further to this recording the pharmacokinetics, drug metabolism, safety and tolerability of the VAL401 formulation in comparison to historical clinical records for risperidone were conducted.

Data from the completed Phase II clinical trial indicated a palliative effect and an improvement of quality of life in the patients treated.  ValiSeek is in receipt of confirmation of acceptance of its Clinical Study Report.  ValiSeek is currently in discussions with potential partners for starting the next clinical trial.  In January 2019, an independent peer reviewed article published in the European Journal of Drug Metabolism and Pharmacokinetics analysed the pharmacokinetic data acquired during the Phase II clinical trial and considered the clinical significance of the VAL401 results in comparison to previously reported data for conventional risperidone, thereby providing a theoretical scientific insight into the activity of the therapeutic.